Please use this identifier to cite or link to this item: http://hdl.handle.net/10637/14366

Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event the international VULCANO randomised clinical trial


Thumbnail

See/Open:
 Safety_Mostaza_BMCCD_2022.pdf
2 MB
Adobe PDF
Title: Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event the international VULCANO randomised clinical trial
Authors : Mostaza Prieto, José María
Suárez Fernández, Carmen
Cosín Sales, Juan
Gómez Huelgas, Ricardo
Brotons Cuixart, Carlos
Pestana Araujo, Francisco
Keywords: Enfermedades cardiovasculares - Prevención.Cardiovascular system - Diseases - Prevention.Enfermedades cardiovasculares - Factores de riesgo.Tablets (Medicine)Medicamentos - Dosificación - Formas.Drugs - Dosage forms.Cardiovascular system - Diseases - Risk factors.Pastillas (Farmacia)
Publisher: Springer Nature
Citation: Mostaza, J. M., Suárez-Fernández, C., Cosín-Sales, J., Gómez-Huelgas, R., Brotons, C., Araujo, F. P., Borrayo, G., Ruiz, E. & VULCANO investigators (2022). Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial. BMC Cardiovascular Disorders, vol. 22, i. 1 (22 dec.), art. 560. DOI: https://doi.org/10.1186/s12872-022-03013-w
Abstract: Background: Cardiovascular (CV) polypills are a useful baseline treatment to prevent CV diseases by combining different drug classes in a single pill to simultaneously target more than one risk factor. The aim of the present trial was to determine whether the treatment with the CNIC-polypill was at least non-inferior to usual care in terms of low-density lipoprotein cholesterol (LDL-c) and systolic BP (SBP) values in subjects at high or very high risk without a previous CV event. Methods: The VULCANO was an international, multicentre open-label trial involving 492 participants recruited from hospital clinics or primary care centres. Patients were randomised to the CNIC-polypill -containing aspirin, atorvastatin, and ramipril- or usual care. The primary outcome was the comparison of the mean change in LDL-c and SBP values after 16 weeks of treatment between treatment groups. Results: The upper confidence limit of the mean change in LDL-c between treatments was below the prespecified margin (10 mg/dL) and above zero, and non-inferiority and superiority of the CNIC-polypill (p = 0.0001) was reached. There were no significant differences in SBP between groups. However, the upper confidence limit crossed the prespecified non-inferiority margin of 3 mm Hg. Significant differences favoured the CNIC-polypill in reducing total cholesterol (p = 0.0004) and non-high-density lipoprotein cholesterol levels (p = 0.0017). There were no reports of major bleeding episodes. The frequency of non-serious gastrointestinal disorders was more frequent in the CNICpolypill arm. Conclusion: The switch from conventional treatment to the CNIC-polypill approach was safe and appears a reasonable strategy to control risk factors and prevent CVD.
Description: Este artículo se encuentra disponible en la siguiente URL: https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-022-03013-w
En este artículo de investigación también participan: Gabriela Borrayo y Emilio Ruiz en representación del grupo de investigadores VULCANO.
URI: http://hdl.handle.net/10637/14366
Rights : http://creativecommons.org/licenses/by/4.0/deed.es
ISSN: 1471-2261 (Electrónico)
Language: es
Issue Date: 22-Dec-2022
Center : Universidad Cardenal Herrera-CEU
Appears in Collections:Dpto. Medicina y Cirugía





Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.